98 results on '"Zerbini, Cristiano"'
Search Results
2. Chronic arthritides and bone structure: focus on rheumatoid arthritis—an update
3. Review for "Relationships Between Obesity and Incidence of Fractures in a Middle‐Aged Population: A Study from the CARTaGENE Cohort"
4. Plain language summary of Pfizer-BioNTech BNT162b2 COVID-19 vaccine safety in participants 16 years or older and protection against COVID-19 in participants 12 years or older
5. In memoriam: Rosa Maria Rodrigues Pereira (1958–2022)
6. Evidence based Latin American Guidelines of clinical practice on prevention, diagnosis, management and treatment of glucocorticoid induced osteoporosis. A 2022 update
7. Review for "Relationships Between Obesity and Incidence of Fractures in a Middle‐Aged Population: A Study from the CARTaGENE Cohort"
8. Definition and management of very high fracture risk in women with postmenopausal osteoporosis: a position statement from the Brazilian Society of Endocrinology and Metabolism (SBEM) and the Brazilian Association of Bone Assessment and Metabolism (ABRASSO)
9. An updated hip fracture incidence rate for Brazil: the Brazilian Validation Osteoporosis Study (BRAVOS)
10. Safety and Efficacy of a Third Dose of BNT162b2 Covid-19 Vaccine
11. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months
12. Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial
13. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study
14. Guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: an update of Brazilian Society of Rheumatology (2020)
15. Emerging Therapies
16. Treatment of knee osteoarthritis with a new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin: a multicenter, randomized, single-blind, non-inferiority clinical trial
17. RHEUMATOID ARTHRITIS ASSOCIATED WITH OSLER-WEBER-RENDU DISEASE: FIRST DESCRIPTION
18. Patient-reported outcomes from a randomized, double-blind, placebo controlled, phase III study of baricitinib versus placebo in patients with moderately to severely active rheumatoid arthritis and an inadequate response to methotrexate therapy: results from the RA-BALANCE study
19. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
20. Switching between Janus kinase inhibitor upadacitinib and adalimumab following insufficient response: efficacy and safety in patients with rheumatoid arthritis
21. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme
22. Romosozumab improves lumbar spine BMD and bone strength greater than alendronate as assessed by quantitative computed tomography and finite element analysis in the ARCH trial
23. Efficacy and Safety of Baricitinib in Chinese Rheumatoid Arthritis Patients and the Subgroup Analyses: Results from Study RA-BALANCE
24. Efficacy and Safety of Long‐Term Baricitinib With and Without Methotrexate for the Treatment of Rheumatoid Arthritis: Experience With Baricitinib Monotherapy Continuation or After Switching From Methotrexate Monotherapy or Baricitinib Plus Methotrexate
25. P209 Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select Phase 3 clinical programme
26. Effects of Odanacatib on Bone Structure and Quality in Postmenopausal Women With Osteoporosis: 5-Year Data From the Phase 3 Long-Term Odanacatib Fracture Trial (LOFT) and its Extension
27. Treatment Mode Preferences in Rheumatoid Arthritis: Moving Toward Shared Decision-Making
28. Burden of rheumatoid arthritis on patients’ work productivity and quality of life
29. Correction to: Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort
30. SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM.
31. FRAX Modelo Brasil e os limites de intervenção médica
32. Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort
33. THU0167 SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM
34. OP0029 SWITCHING BETWEEN THE JAK1-SELECTIVE INHIBITOR-UPADACITINIB AND ADALIMUMAB FOLLOWING INITIAL NON-RESPONSE: CLINICAL AND FUNCTIONAL OUTCOMES AMONG RHEUMATOID ARTHRITIS PATIENTS
35. Incidence and excess mortality of hip fractures in a predominantly Caucasian population in the South of Brazil
36. 074 Summary of indirect comparison to evaluate efficacy of baricitinib with targeted synthetic and biologic disease anti-rheumatic drugs in patients with rheumatoid arthritis
37. Serum 25-hydroxy-vitamin D and the risk of fractures in the teriparatide versus risedronate VERO clinical trial
38. Maintenance of low disease activity and remission with etanercept–disease-modifying antirheumatic drug (DMARD) combination therapy compared with treatment with DMARDs alone in Latin American patients with active rheumatoid arthritis
39. Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis
40. The brazilian FRAX model: an introduction
41. Romosozumab FRAME Study: A Post Hoc Analysis of the Role of Regional Background Fracture Risk on Nonvertebral Fracture Outcome
42. Teriparatide vs risedronate for osteoporosis – Authors' reply
43. 219 Safety summary results of baricitinib focusing on serious infections events and preselected comorbidities
44. 233 Durability, maintenance and effects of dose reduction following prolonged treatment with baricitinib
45. Effects of Teriparatide Compared with Risedronate on the Risk of Fractures in Subgroups of Postmenopausal Women with Severe Osteoporosis: The VERO Trial
46. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial
47. Effect of Glucocorticoids on the Clinical and Radiographic Efficacy of Tofacitinib in Patients with Rheumatoid Arthritis: A Posthoc Analysis of Data from 6 Phase III Studies
48. Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment
49. Maintenance of remission with combination etanercept–DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access
50. Baricitinib, Methotrexate, or Combination in Patients With Rheumatoid Arthritis and No or Limited Prior Disease-Modifying Antirheumatic Drug Treatment
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.